Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Benoxaprofen improves psoriasis. A double-blind study.

K Kragballe, T Herlin

    Archives of Dermatology
    |July 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Standardized reporting and quantification of whole-body MRI findings in children with chronic non-bacterial osteomyelitis treated with pamidronate.

    Pediatric rheumatology online journal·2022
    Same author

    Pamidronate in chronic non-bacterial osteomyelitis: a randomized, double-blinded, placebo-controlled pilot trial.

    Scandinavian journal of rheumatology·2020
    Same author

    Defining consensus opinion to develop randomised controlled trials in rare diseases using Bayesian design: An example of a proposed trial of adalimumab versus pamidronate for children with CNO/CRMO.

    PloS one·2019
    Same author

    Clinical Outcome and Long-term Remission in JIA.

    Current rheumatology reports·2017
    Same author

    Remission rate is not dependent on the presence of antinuclear antibodies in juvenile idiopathic arthritis.

    Clinical rheumatology·2017
    Same author

    Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis.

    Journal of the European Academy of Dermatology and Venereology : JEADV·2016
    Same journal

    Scoring With SCORTEN-Reply.

    Archives of dermatology·2017
    Same journal

    Comparison of Early and Late Latent Syphilis- Colorado, 1991.

    Archives of dermatology·2016
    Same journal

    Case of Rhinoscleroma.

    Archives of dermatology·2016
    Same journal

    Cutaneous Fungal Infections.

    Archives of dermatology·2016
    Same journal

    An Ulcerated Plaque in a Gay Man.

    Archives of dermatology·2016
    Same journal

    Solitary Violaceous Nodule on the Face.

    Archives of dermatology·2016
    See all related articles

    Benoxaprofen, a 5-lipoxygenase inhibitor, showed significant improvement in 75% of psoriasis vulgaris patients. However, serious side effects like photosensitivity were common, warranting further research into lipoxygenase inhibitors for psoriasis.

    Area of Science:

    • Dermatology
    • Pharmacology
    • Biochemistry

    Background:

    • Elevated lipoxygenase compounds are implicated in the pathophysiology of psoriasis vulgaris.
    • Understanding the role of lipoxygenase pathways is crucial for developing targeted psoriasis therapies.

    Purpose of the Study:

    • To assess the therapeutic efficacy and safety of benoxaprofen, a 5-lipoxygenase inhibitor, in patients with psoriasis vulgaris.
    • To investigate the role of 5-lipoxygenase inhibition in managing psoriatic lesions.

    Main Methods:

    • A double-blind, randomized clinical study involving 40 patients diagnosed with psoriasis vulgaris.
    • Patients received either 600 mg of oral benoxaprofen daily or a placebo for eight weeks.

    Main Results:

    Related Experiment Videos

    • Benoxaprofen therapy resulted in excellent treatment outcomes in approximately 75% of patients.
    • Minimal improvement was observed in the placebo group.
    • Common side effects included photosensitivity, onycholysis, milia, diarrhea, and edema, with two patients discontinuing treatment due to photosensitivity.

    Conclusions:

    • Benoxaprofen demonstrates significant potential in treating psoriasis vulgaris, likely through direct inhibition of epidermal 5-lipoxygenase or indirect reduction of phagocyte accumulation.
    • Despite notable side effects, lipoxygenase-inhibiting agents warrant continued investigation for psoriasis treatment.